Orphan Therapeutics Accelerator Announces Foundational Partnerships
The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions, today announced collaborative partnerships with rare disease-focused global biotech and pharmaceutical companies, a contract development and manufacturing organization (CDMO), contract research organization (CRO), and AI-based platform providers, establishing the foundation for a new development and commercialization pathway for ultra-rare disease treatments.
